Weight Control Treatment: An Overview of GLP-1 and GLP/GIP Receptor Agonists

Course overview

GLP-1 RAs and tirzepatide can produce significant and long-lasting weight loss combined with lifestyle interventions. Although GLP-1 RAs can produce weight loss, some people do not respond to treatment and don't lose weight. Cost, convenience, tolerability, and comorbidities are primary factors that should drive the decision about which medication to use. Comorbidities are also an especially important consideration. New studies suggest that GLP-RAs might help treat alcohol use disorder, Parkinson's disease, sleep apnea, and other diseases. The potential for adverse effects of the GLP-1 RAs are typically mild and transitory, although serious adverse effects have rarely been reported. An individualized assessment that focuses on patient comorbidities and prudent monitoring is essential. Treatment will need to be chronic. Lifestyle interventions must be considered when prescribing semaglutide, liraglutide, and tirzepatide. Diet, exercise, and behavioral interventions have been highlighted.